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NRELATED ADULT CORD BLOOD TRANSPLANTS FOR ADULTS WITH
CUTE LEUKEMIA: COMPARISON WITH OTHER STEM CELL SOURCES
luckman, E. Eurocord, Hospital Saint Louis, Paris, France
Unrelated cord blood transplant is an option for adults who lack
n HLA identical bone marrow donor. Eurocord has analyzed
esults in 171 patients with malignancies and compared with HLA
dentical unrelated bone marrow transplant or to haploidentical
eripheral blood related transplants.
Results in adults: One-hundred and seventy one patients were
ransplanted after 1997. Median age was 29 years (15-55), and
edian follow-up time was 18 months (1-71). Most patients had
cute or chronic leukemia (n  142, 83%), 91 (53%) were trans-
lanted in advanced phase and 32 (19%) had failed an autologous
ransplant. Most patients (87%) received an HLA incompatible CB
nit with 1-2 HLA mismatches. At infusion, the median number of
ucleated cells (NC) and CD34 cells was 2.1  107/kg and 1 
05/kg, respectively. The cumulative incidence (CI) of neutrophil
ecovery at day 60 was 72  3% with a median of 28 days (11-57).
higher NC and use of hematopoietic growth factors were inde-
endently associated with faster neutrophil recovery. The CI of
rade II-IV acute-GVHD was 32  4% and it was not associated
ith the number of HLA mismatches. The 2-year CI of chronic-
VHD, transplant-related-mortality and relapse were 36  10%,
1  4% and 22  4%, respectively. At 2-years, disease-free-
urvival (DFS) for patients transplanted in early, intermediate and
dvanced phase of disease was 41  9%, 34  10% and 18  4%,
espectively. In multivariate analyses, advanced status of the disease
as an adverse factor for relapse and DFS.
Comparison with HLA identical unrelated bone marrow
ransplants: Eurocord and EBMT have performed a matched pair
nalysis to compare the results of UCB and BMT from unrelated
onors in adults with acute leukemia. Eighty-one patients receiving
nrelated donor UCB (90% HLA-mismatched) were matched for
ge, diagnosis, status of disease at transplant and use of total body
rradiation and compared with 162 recipients of unmanipulated
LA-matched unrelated donor BM. Neutrophil recovery was de-
ayed in recipients of UCB and incidence of acute GVHD  grade
I was higher in those receiving BM. The 2-year cumulative inci-
ence of chronic GVHD, TRM, leukemia relapse, 2-year proba-
ility of survival and leukemia-free survival were not signiﬁcantly
ifferent.
Comparison with haploidentical related peripheral blood
ransplant: We have compared the outcome in 229 patients re-
eiving a haplo mismatched related transplant to 139 patients who
eceived a mismatched unrelated cord blood transplant. There
ere 220 AML and 148 ALL which were analyzed separately. In
ML, engraftment was faster in patients with haplo transplant.
here was more GVH in the UCBT group (23 vs 5%). Transplant
elated mortality (58 vs 46%) and rate of relapse (24 vs 18%) were
ot different. Leukemia free survival was identical (30 vs 24%). In
LL engraftment and GVH rates were similar to the AML pa-
ients, TRM was identical after haplo or CB. LFS was higher in CB
han in haplo (36 vs 13%). The difference was more signiﬁcant in
atients transplanted in CR2 or more advanced disease.
Conclusion: UCBT is a clear alternative for adults with he-
atological malignancies lacking an HLA-matched related or
nrelated donor. These data suggest that, despite increased
LA disparity, UCB from unrelated donors offers comparable
esults to matched unrelated BM in adults with acute leukemia,
eading to the conclusion that the donor search process for BM
nd UCB from unrelated donors should be started simulta-
eously in adults, especially in patients with acute leukemia
here the time factor is very important. The choice of units
ontaining a higher NC and a policy of earlier transplantation
re likely to provide better results.
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ORD BLOOD TRANSPLANTATION TO ADULT PATIENTS: A NEW YORK
LOOD CENTER UPDATE
ubinstein, P. Stevens, C.E., Scaradavou, A. National Cord Blood
rogram–New York Blood Center, New York, NY
Since 1993, the National Cord Blood Program has provided cord
lood transplants to 1750 recipients worldwide, of whom 396 16
ears old (22.6%). Of the adults, 65% were 25 years old, 90%
ad hematologic malignancies, 33% had advanced disease (IBMTR
lassiﬁcation), 13% had received a prior auto or allograft and 11%
eceived double-unit transplants. Of single-unit transplant recipi-
nts, 22% had 1, 66% had 2 and 10% had 3 HLA mismatches
HLA-A and -B at serological resolution level, DRB1 at the allele
evel). TNC doses were below 5  107 in all but 5 patients.
ngraftment was associated with TNC dose (P  0.004) and
LA-matching (p  0.003), especially when recipients of mis-
atched only in the GvH direction were counted as matched (p 
.001). Signiﬁcant differences in the probability of engraftment
ere also related to the conditioning regimens and to the use of
ouble unit transplantation. Acute GvHD grade III–IV developed
n 25% of cases, and was lower (10%) in cases without HLA
ismatches in the GvHD direction. This was not signiﬁcant in this
ample, however. The probability of relapse was 15% and was
ower in cases with lower IBMTR risk factors (NS in this sample).
ithin the adult group (age  16-67), age at transplantation was
ot signiﬁcantly related to the probability of survival at 1 or 5
ears. The difference in 1 year survival between recipients of grafts
ith  and grafts with 2.5  107 was not signiﬁcant (28% vs.
4%). The absence of HLA rejection mismatches was signiﬁcantly
ssociated: with survival at 1 year (survival  68% vs. 27%, P 
.005). Overall survival was 23% at 5 years. Engraftment and
urvival were signiﬁcantly better in a group of 45 patients given a
wo-unit transplant, the majority of which also were treated with
udarabine-containing regimens. These results extend the data on
dult recipients of cord blood grafts beyond those previously reported.
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ORD BLOOD TRANSPLANTS FOR ADULTS USING MYELOABLATIVE
ONDITIONING
akahashi, S. Division of Molecular Therapy, The Institute of Medical
cience, The University of Tokyo, Tokyo, Japan
Cord blood transplantation (CBT) from unrelated donors has
omparable efﬁcacy to bone marrow transplantation (BMT) from
nrelated donors and can restore hematopoiesis with acceptable
oxicities in adults. We studied the clinical outcomes of 92 adult
atients with hematological malignancies who received CBT from
nrelated donors after myeloablative conditioning. Overall rate of
igh-risk patients was 58% and median follow-up was 22 months
range: 1 to 82 months). Three patients died within 28 days of
BT and primary graft failure occurred in 3 of 89 evaluable
ecipients. A median time of neutrophil (500/L) and platelet (
0,000/L) engraftment were 22 and 40 days. The cumulative
ncidence of grades II to IV and grades III and IV acute GVHD
ere 52% and 8%. The number of patients suffered from any
ype of chronic GVHD was 67 of 73 evaluable recipients (92%).
wenty-two was extensive type (30%). Despite using human leu-
ocyte antigen (HLA)-mismatched cord blood graft in all cases,
apid tapering of immunosuppressants after transplantation and
he low incidence to treat severe acute GVHD with steroid,
VHD-related death was only 2 of all 23 deaths (9%). The 1-year
robability of transplant-related mortality (TRM) was 20% and
he 2-year probability of relapse was 18%. The 2-year probabilities
f disease-free survival (DFS) were 95% in standard-risk patients
N  39) and 60% in high-risk patients (N  53). We speculated
hat the immune reconstitution process over a period of several
onths after CBT might have contributed to those promisinglinical results. Circulating T cell counts normalized after 3
onths for CD8 and 4 months for CD4 in our CBT recipients,
b
s
t
m
c
ﬁ
c
i
f
t
C
r
c
c
m
o
t
a
U
B
W
P
a
i
c
h
c
m
v
1
v
m
(
m
r
P
t
m
U
r
d
(
i
e
(
6
I
C
1
R
t
p
4
a
i
p
p
o
t
C
T
L
T
K
O
v
t
w
t
(
G
c
a
(
M
b
G
s
N
(
3
T
C
c
f
g
e
N
I
i
a
n
G
g
o
U
L
B
C
c
g
a
g
c
a
w
e
a
s
(
M
p
5
c
s
m
d
a
p
v
(
s
c
p
h
r
3
s
t
t
r
Abstracts
Both of which were signiﬁcantly faster than in previously published
tudies. After T cell recovery, peripheral blood T cells moved from
he naive to the central memory fraction immediately, and then
oved to the effector memory fraction. A naive subset of CD4 T
ells remained (median: 38 cells/L on day 90, n  12) during the
rst 3 months, which was signiﬁcantly higher than in the BMT
ontrol (median: 9 cells/L on day 90, n  5, p  0.015). To
nvestigate whether these T cells with memory phenotype are
unctional, we analyzed antigen-speciﬁc T-cell recovery using cy-
omegalovirus (CMV) as a speciﬁc antigen. CMV-responsive
D4 T cells were detected within the ﬁrst 4 months in all
ecipients with positive CMV antigenemia (n  13), but CD8 T
ells were detected only in 5 out of 13 cases. To conclude, naive
ord blood T cells rapidly increased in number and adopted a
emory phenotype showing cytokine-production and antigen-rec-
gnition capacity in the early phase after CBT. These data suggest
hat mature T lymphocytes in cord blood have unique properties
nd contribute to the favorable clinical outcome of CBT.
4
MBILICAL CORD BLOOD TRANSPLANTATION AFTER A NON-MYELOA-
LATIVE THERAPY IN HIGH RISK ADULTS AND ADOLESCENTS
agner, J.E., Brunstein, C., Barker, J. Blood and Marrow Transplant
rogram, University of Minnesota, Minneapolis, MN
Bone marrow transplantation (BMT) in adults is associated with
high risk of graft-versus-host disease (GVHD), opportunistic
nfection and regimen related toxicity. For these reason, umbilical
ord blood (UCB) after a non myeloablative preparative regimen
as been explored. The underlying hypothesis is that umbilical
ord blood T cells will be sufﬁciently alloreactive to effect engraft-
ent in the non myeloablative setting. Fifty-one adults with ad-
anced hematologic malignancies [median age 49 years (range
9-60)], ineligible for myeloablative conditioning by virtue of ad-
anced age (73%), extensive prior therapy (42%) or serious co-
orbidities/poor ﬁtness (31%) received UCB transplantation
UCBT) after cyclophosphamide 50 mg/kg, ﬂudarabine 200 mg/
2, and 200 cGy TBI. Immunosuppression was with cyclospo-
ine-A to at least day 100 and mycophenolate mofetil to day 30.
atients with no combination chemotherapy in the 6 months prior
o transplant also received ATG during conditioning. Approxi-
ately 1/4 received single and 3/4 received double UCB grafts.
nits were predominantly 1-2 antigen HLA mismatched with the
ecipient. The incidence of sustained neutrophil engraftment of
onor origin was 89% (95% CI, 81-97) at a median of 8 days
range 5-32). Stratiﬁed into those with and without chemotherapy
n the prior 4 months, the cumulative incidence of sustained donor
ngraftment was 98% (95% CI: 94-100) and 64% (95% CI, 39-89)
p  0.03). The incidence of platelet recovery (50,000/L) was
8% (95% CI, 53-83). The incidences of grade II-IV and grade
II-IV acute GVHD were 63% (95% CI: 49-73) and 25% (95%
I: 14-36) at day 100, and chronic GVHD was 28% (95% CI:
6-40) at 1 year. TRM was 19% (95% CI: 9-29) at day 180.
egression of relapsed or persistent disease has been seen in pa-
ients with myelodysplasia and intermediate and low grade lym-
hoid malignancies. The probability of overall survival at 1 year is
4% (95% CI: 30-58). Notably, only ﬁtness and not age was
ssociated with poor outcome. These data suggest that the regimen
s well tolerated and sufﬁcient for engraftment particularly in
atients with chemotherapy in the preceding 4 months. This ap-
roach extends access to transplant to many adults who would
therwise be ineligible based on lack of donor and/or inability to
olerate high-dose conditioning.
5
OMPARISON OF ADULT ALLOGENEIC UMBILICAL CORD BLOOD
RANSPLANTATION BETWEEN MYELOABLATIVE AND NON-MYELOAB-
ATIVE CONDITIONING REGIMENS
ashiro, H.1, Kozai, Y.2, Goto, M.1, Noguchi, M.1, Shirasaki, R.1,
awasugi, K.1, Kodo, H.2, Shirafuji, N.2 1. Department of Hematology/
ncology, Teikyo University School of Medicine, Tokyo, Japan; 2. Di-
ision of Transfusion Medicine, Fuchu Metropolitan Hospital
Aim: To make clear the feasibility of non-myeloablative condi-
ioning on adult allogeneic umbilical cord blood transplantation,
m
t
B & M Te compared the result between patients receiving the myeloabla-
ive transplantation and the non-myeloablative transplantation
NST) in point of the engraftment, and the incidence of acute
VHD.
Patients and Methods: Patients who were underwent umbilical
ord blood transplantation during May 1999 to Mar 2005 were
nalyzed retrospectively. The myeloablative group: 30 patients
median age, 33) with AML (n 10), ALL (n 10), NHL (n 6),
DS (n  3), and CML (n  1). Conditioning consisted of total
ody irradiation (TBI)-based regimens or busulfan-based ones.
VHD prophylaxis was with cyclosporine (CyA) alone, CyA with
hort-term Methotrexate (s-MTX), or Tacrolimus with s-MTX.
ST group: 22 patients (median age, 55) with AML (n  6), ALL
n  1), MDS (n  3), CMMoL (n  1), NHL (n  7), HD (n 
), and CLL (n  1). Conditioning regimen consisted mostly of
BI combined with Fludarabine. GVHD prophylaxis was with
yA, CyA with MMF, or Tacrolimus. The median transplanted
ell number, and HLA disparity were similar between two groups.
Results: The rate of engraftment failure including conditioning
ailure, and autologous recovery was 27% in the myeloablative
roup and 32% in NST group, respectively. Neutrophils were
ngrafted at day 23 (median) and at day 21 in the myeloablative and
ST group, respectively. The cumulative incidence of grade
II-IV acute GVHD was 26% in the myeloablative group and 40%
n NST group, respectively.
Conclusion: There were no signiﬁcant differences in the prob-
bility of engraftment and in the duration to the engraftment of
eutrophils between two groups. The incidence of grade III-IV
VHD in NST group was higher than that in the myeloablative
roup. Further observations are needed to ascertain the feasibility
f NST using allogeneic umbilical cord blood.
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MBILICAL CORD BLOOD (UCB) TRANSPLANTATION FOR INDOLENT
YMPHOID MALIGNANCIES
arker, J.N.1, Wagner, J.E.2 1. Memorial Sloan-Kettering Cancer
enter, New York, NY; 2. University of Minnesota, MN
Multiple studies have suggested patients with refractory or re-
urrent Non-Hodgkin’s lymphoma (NHL) can beneﬁt from allo-
eneic transplantation with reduced risk of post-transplant relapse
s compared to that seen after autologous transplantation due to a
raft-versus-lymphoma (GVL) effect. However, widespread appli-
ation of allografting has been limited by lack of suitable donors
nd high transplant-related mortality (TRM) early post transplant
hen conventional myeloablative conditioning is used. Non-my-
loablative (NMA) conditioning is associated with reduced TRM
nd has been successful in patients transplanted with matched
ibling donors for follicular NHL, chronic lymphocytic leukemia
CLL), and mantle cell lymphoma (MCL). The University of
innesota has investigated NMA UCB transplantation (UCBT) in
atients without matched sibling donors using conditioning with
0 mg/kg Cyclophosphamide, 200 mg/m2 Fludarabine and 200
Gy TBI with cyclosporine and mycophenolate mofetil immuno-
uppression. This approach in patients with advanced hematologic
alignancies has been associated with a high incidence of sustained
onor engraftment and a low incidence of TRM despite older age
nd/or extensive prior therapy provided the recipient has good
erformance status. Sixteen patients aged 37-67 years with ad-
anced or refractory follicular NHL (n 7), CLL (n 6) or MCL
n  3) were transplanted using this approach. Thirteen had
ustained donor engraftment. Grade II–IV acute and extensive
hronic graft-versus-host disease (GVHD) was seen in 12 and 6
atients, respectively. Four patients (3 follicular NHL and 1 CLL)
ave died with progressive disease and 12 are alive in complete
emission between 180 and 1214 days after transplant. Two of the
patients with failure of donor engraftment were salvaged with a
ingle cycle of CVP. This lack of intensive combination chemo-
herapy immediately prior to transplant may have contributed to
heir risk for graft rejection. Two patients with follicular NHL
equired the addition of Rituximab post-transplant to achieve re-
ission. Interestingly, 2 of 3 patients (both with CLL) who had
ransient donor engraftment and subsequent graft rejection are in
929
